Frontline compliance requires expert juggling
Posted on 04-18-2019 by Lisa Thompson

There’s no room for clowning about when it comes to risk management and maintaining the integrity of international business. According to records of ancient Chinese history, the armies of the Chu and Song states were facing each other in readiness for battle in 630 BC when a Chu warrior, Xiong... Read More

2 Reasons why companies need to conduct risk assessments of their own compliance programs
Posted on 10-08-2018 by Lisa Thompson

As the aftermath of corporate corruption and ethics scandals continue to play out in news headlines and courtrooms, spurring a continued search for expert advice and best practices on mitigating compliance risk . So, when a former compliance expert at the U.S. Department of Justice (DOJ) and a Harvard... Read More

A new No. 1: Petrobras agrees to biggest FCPA settlement
Posted on 10-05-2018 by Lisa Thompson

Petrobras has reached a $1.78 billion settlement with the DOJ and SEC over bribes to politicians and political parties in Brazil. This is the first time an enforcement action over FCPA violations has exceeded a billion dollars. The amount is bigger than the nearest two settlements combined, and the case... Read More

3 Reasons to Combine Due Diligence & Risk Monitoring
Posted on 10-03-2018 by Lisa Thompson

Companies are exposed to regulatory, financial, reputational and strategic risks, and the number of countries and NGOs with compliance expectations is on the rise. The best way to proactively manage these expectations? Risk-based due diligence and ongoing monitoring. 1—Regulatory risks... Read More

Why the Energy Sector Needs Better Due Diligence & Risk Monitoring
Posted on 08-23-2018 by Lisa Thompson

No industry is impervious to bribery and corruption risk, but companies linked to energy industries, in particular, face elevated risks in order to reap the equally-high rewards. It’s a topic we’ve touched on in blog posts on Unaoil and Petrobras . But anti-bribery and corruption regulations... Read More

Why Pharma & Biomed Companies’ Risk Analysis Processes are Due for a Check-Up
Posted on 07-18-2018 by Lisa Thompson

Just three years ago, Teva Pharmaceuticals, a drug-maker in Israel, disclosed to both the U.S. Securities & Exchange Commission and the U.S. Department of Justice that an on-going internal probe had revealed possible violations of the Foreign Corrupt Practices Act (FCPA) and/or local laws. Ultimately... Read More